Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
RIGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.48 - $29.82
Previous CloseN/A
Volume99.93K
Average Volume (3M)245.00K
Market Cap
$348.86M
Enterprise Value$284.66M
Total Cash (Recent Filing)$56.75M
Total Debt (Recent Filing)$59.97M
Price to Earnings (P/E)20.1
Beta2.38
Next Earnings
May 06, 2025EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.97
Shares Outstanding17,862,959
10 Day Avg. Volume276,041
30 Day Avg. Volume245,004
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.04
Price to Cash Flow (P/CF)6.30
P/FCF Ratio5.60
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.77
Enterprise Value/Ebitda10.18
Forecast
1Y Price Target
$39.00Price Target Upside100.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Rigel News
PremiumCompany Announcements
Rigel Pharmaceuticals Appoints Dr. Frohlich to Board
PremiumCompany Announcements
Rigel Pharmaceuticals Reports Record Sales and Strategic Growth
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRigel Pharmaceuticals exceeded earnings expectations for both the fourth quarter and full year, indicating strong financial performance.
International ExpansionApproval from the Korean Ministry of Food and Drug Safety for Tavalisse boosts Rigel's presence in the international market.
Bears Say
Safety ConcernsRigel announced the issuance of a Dear Health Care Provider letter regarding a new safety signal for Gavreto relating to increased risk of severe infections.
---
Ownership Overview
5.45% Insiders
25.40% Mutual Funds
22.37% Other Institutional Investors
35.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $7.48 and its highest was $29.82 in the past 12 months.
What is Rigel’s market cap?
Rigel’s market cap is $348.86M.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is May 06, 2025 which is in 55 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Mar 04, 2025. The company reported $0.8 earnings per share for the quarter, beating the consensus estimate of $0.451 by $0.349.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is 0.09.
How many shares outstanding does Rigel have?
Rigel has 17,862,959 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of $0.8 in its last earnings report, beating expectations of $0.451. Following the earnings report the stock price went down -8.107%.
Which hedge fund is a major shareholder of Rigel?
Currently, no hedge funds are holding shares in RIGL
---
Rigel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.00 (100.10% Upside)
$39.00 (100.10% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 10.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $424.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.8%
Last 30 Days ▼ 9.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.07%
12-Months-Change
Fundamentals
Return on Equity
531.78%
Trailing 12-Months
Asset Growth
320.74%
Trailing 12-Months
Company Description
Rigel
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
---
RIGL Company Deck
---
RIGL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong year for Rigel Pharmaceuticals, marked by record-breaking sales, successful product integration, and global expansion. Despite some reliance on inventory build and pending decisions on study designs, the company's achievements in financial performance and R&D progress contribute to a predominantly positive outlook.Read More>---
RIGL Stock 12 Month Forecast
Average Price Target
$39.00
▲(100.10% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Alkermes
―
BioMarin Pharmaceutical
―
Incyte
―
Vertex Pharmaceuticals
―
Best Analysts Covering RIGL
1 Year
1 Year Success Rate
12/15 ratings generated profit
1 Year Average Return
+50.69%
reiterated a buy rating 9 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +50.69% per trade.
---